Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands		9 Months Ended
		Sep. 30, 2018	Sep. 30, 2017
Cash flows from operating activities:
Net loss		$ (80,682)	$ (530,113)
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Depreciation and amortization		1,977	17,674
Asset impairment charges		5,073	329,097
Amortization of debt discount		20,526	20,325
Unrealized foreign currency transaction losses, net		(111)	1,276
Stock compensation expense		13,244	24,078
Gain on sale of business		(168,955)	0
(Gain) loss on sale of assets		(7,026)	72
Loss on short-term investments		41,416	0
Deferred tax benefit		0	(89,992)
Reserve for excess or obsolete inventory		(392)	1,797
Changes in contingent purchase price		(258)	(11,788)
Changes in operating assets and liabilities:
Accounts receivable		6,195	14,476
Inventory, net		2,202	1,976
Prepaid expenses and other assets		5,549	5,886
Accounts payable		(2,681)	(16,898)
Accrued expenses		(58,774)	(5,245)
Other current liabilities		(4,317)	(11,707)
Payments on contingent purchase price		(59)	(52,499)
Other liabilities		4,305	(3,189)
Net cash used in operating activities		(222,768)	(304,774)
Cash flows from investing activities:
Proceeds from sale of assets		9,900	0
Purchases of fixed assets		(7)	(4,525)
Purchases of available for sale securities		0	(131,560)
Proceeds from maturities and sales of available for sale securities		0	89,344
Proceeds from sale of business		166,383	0
Net cash provided by (used in) investing activities		176,276	(46,741)
Cash flows from financing activities:
Proceeds from issuances of common stock, net		15,595	40,708
Payments on contingent purchase price		(511)	(10,119)
Repayments of convertible senior notes		0	(55,000)
Purchase of shares of non-controlling interest		0	(167)
Net cash provided by (used in) financing activities		15,084	(24,578)
Effect of exchange rate changes on cash		(1,374)	1,008
Decrease in cash, cash equivalents and restricted cash		(32,782)	(375,085)
Cash, cash equivalents and restricted cash at beginning of period		156,900	546,867
Cash, cash equivalents and restricted cash at end of period	[1]	124,118	171,782
Supplemental disclosure of cash flow information:
Interest paid		21,069	22,561
Non-cash investing and financing activities
Issuance of common stock upon conversion of convertible notes		0	32,018
Receipt of common stock upon settlement of 2017 Note hedge		0	40,015
Issuance of common stock upon the exercise of the 2017 Warrants		0	887
Reconciliation of cash, cash equivalents and restricted cash
Total cash, cash equivalents and restricted cash at end of period		$ 156,900	$ 546,867

[1] The following table provides a reconciliation of cash, cash equivalents and restricted cash to amounts reported within the condensed consolidated balance sheet: Nine Months Ended September 30, 2018 2017Reconciliation of cash, cash equivalents and restricted cash Cash and cash equivalents$118,708 166,734Restricted cash5,410 5,048Total cash, cash equivalents and restricted cash at end of period$124,118 $171,782